🟢 GRAIL is trading 7.6% up in pre-market after FDA panel favored Galleri approval

GRAIL is trading at $116.80, up +7.6%, after a favorable September 23 FDA advisory-panel vote supporting Galleri’s approval.

• The panel voted 7–2, with one abstention, that Galleri’s benefits outweighed its risks; safety received unanimous support.
• The FDA is not bound by the recommendation, and a final decision is expected in the coming months.
• The catalyst is company-specific, despite broader biotech strength.